Tempest Therapeutics, Inc. — Director's Dealing 2021

Sep 21, 2021

SEC Form 4/A — Form 4/A

Issuer: Tempest Therapeutics, Inc. (TPST)
CIK: 0001544227
Period of Report: 2021-07-01

Reporting Person: Xu Stella (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-01	Stock Option (Right to Buy)	$11.07	A	6635	Acquired	2031-06-30	Common Stock (6635)	Direct

Footnotes

F1: Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

F2: The reporting person holds these securities for the benefit of Quan Venture Fund I, L.P. ("Quan Capital"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The reporting person is amanager of Quan Venture Partners I, L.L.C. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest. This report on Form 4 shall not be deemed anadmission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.